`Patent No. 9,326,945 B2
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`BRISTOL-MYERS SQUIBB CO.
`and PFIZER INC.,
`Patent Owners.
`
`IPR No. 2018-00892
`Patent No. 9,326,945 B2
`
`DECLARATION OF AMY K. WIGMORE IN SUPPORT OF
`MOTION FOR ADMISSION PRO HAC VICE
`
`BMS 2002
`MYLAN v. BMS
`IPR2018-00892
`
`
`
`IPR No. 2018-00892
`Patent No. 9,326,945 B2
`
`I, Amy K. Wigmore, declare as follows:
`
`1.
`
`I obtained a B.A. from the University of Massachusetts in 1992 and a
`
`J.D. from the Harvard Law School in 1995.
`
`2.
`
`I am currently a partner in the law firm of Wilmer Cutler Hale and
`
`Dorr LLP. I was admitted to the Massachusetts Bar in January of 1996 and the
`
`District of Columbia Bar in December of 1996. I have been practicing law for
`
`over 20 years. For more than 11 years, my practice has focused primarily on
`
`patent litigation. Over the course of my career, I have been counsel in dozens of
`
`patent litigations.
`
`3.
`
`I am a member in good standing of the Bars of the Commonwealth of
`
`Massachusetts and District of Columbia. I am admitted to practice before the U.S.
`
`District Courts for the District of Columbia, District of Colorado, and District of
`
`Massachusetts. I am also admitted to practice before the U.S. Court of Appeals for
`
`the Federal Circuit, the D.C. Circuit, and the Sixth Circuit, as well as the Supreme
`
`Court of the United States. I am also admitted to practice before the District of
`
`Columbia Court of Appeal and the Supreme Judicial Court of Massachusetts.
`
`4.
`
`My Massachusetts Bar membership number is 629275. My District of
`
`Columbia Bar membership number is 453164.
`
`5.
`
`In the past three years, I have appeared pro hac vice before the Office
`
`in the following proceedings: Apotex Inc. v. OSI Pharmaceuticals Inc., IPR2016-
`
`– 1 –
`
`
`
`IPR No. 2018-00892
`Patent No. 9,326,945 B2
`
`01284 (pro hac vice granted); OSI Pharmaceuticals, LLC v. Arch Development
`
`Corp., IPR2016-01034 (pro hac vice granted); Boehringer Ingelheim GmbH v.
`
`AbbVie Biotechnology Ltd., IPR2016-00408 (pro hac vice granted); Boehringer
`
`Ingelheim GmbH v. AbbVie Biotechnology Ltd., IPR2016-00409 (pro hac vice
`
`granted); Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd., IPR2016-00188
`
`(pro hac vice granted); Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd.,
`
`IPR2016-00189 (pro hac vice granted); Coherus BioSciences Inc. v. AbbVie
`
`Biotechnology Ltd., IPR2016-00172 (pro hac vice granted).
`
`6.
`
`I have an established familiarity with the subject matter of U.S. Patent
`
`No. 9,326,945 (the ’945 patent), the ’945 patent’s file history, and the prior art at
`
`issue in this proceeding. I have been representing Bristol-Myers Squibb Co. and
`
`Pfizer Inc. in connection with matters concerning the ’945 patent since 2015 and
`
`currently represent Bristol-Myers Squibb Co. and Pfizer Inc. in the related district
`
`court cases involving the ’945 patent identified in Patent Owners’ Mandatory
`
`Notices. I have also recently represented other pharmaceutical companies,
`
`including, among others, OSI Pharmaceuticals, Inc., AbbVie, Inc.,
`
`GlaxoSmithKline plc, and Wyeth in intellectual property matters before federal
`
`district courts and appellate courts, including matters involving formulation
`
`technology.
`
`7.
`
`I have never been suspended or disbarred from practice before any
`
`– 2 –
`
`
`
`
`
`
`court or administrative body.
`
`
`
`
`IPR No. 2018-00892
`Patent No. 9,326,945 B2
`
`8.
`
`I have never had a court or administrative body deny my application
`
`for admission to practice.
`
`9.
`
`I have never had any sanctions or contempt citations imposed on me
`
`by any court or administrative body.
`
`10.
`
`I have read and will comply with Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.
`
`11.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like are punishable by fine, imprisonment, or both, under
`
`Section 1001 of Title 18 of the United States Code.
`
`
`
`– 3 –
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: May 14, 2018
`
`
`
`
`IPR No. 2018-00892
`Patent No. 9,326,945 B2
`
`Respectfully submitted,
`
`
`
`
`/Amy K. Wigmore/
`Amy K. Wigmore
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`1875 Pennsylvania Ave NW
`Washington, DC, 20006
`Amy.Wigmore@wilmerhale.com
`Tel.: 202-663-6096
`Fax: 202-663-6363
`
`– 4 –
`
`